• Something wrong with this record ?

The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line

Kovár L, Strohalm J, Chytil P, Mrkvan T, Kovár M, Hovorka O, Ulbrich K, Ríhová B.

. 2007 ; 18 (3) : 894-902.

Language English Country United States

Doxorubicin is one of the most potent anti-tumor drugs with a broad spectrum of use. To reduce its toxic effect and improve its pharmacokinetics, we conjugated it to an HPMA copolymer carrier that enhances its passive accumulation within solid tumors via the EPR effect and decreases its cytotoxicity to normal, noncancer cells. In this study, we compared the antiproliferative, pro-survival, and death signals triggered in EL-4 cancer cells exposed to free doxorubicin and doxorubicin conjugated to a HPMA copolymer carrier via either enzymatically (PK1) or hydrolytically (HYD) degradable bonds. We have previously shown that the intracellular distribution of free doxorubicin, HYD, and PK1 is markedly different. Here, we demonstrated that these three agents greatly differ also in the antiproliferative effect and cell death signals they trigger. JNK phosphorylation sharply increased in cells treated with HYD, while treatment with free doxorubicin moderately decreased and treatment with PK1 even strongly decreased it. On the other hand, treatment with free doxorubicin greatly increased p38 phosphorylation, while PK1 and HYD increased it slightly. PK1 also significantly increased ERK phosphorylation, while both the free doxorubicin and HYD conjugate slightly decreased it. Long-term inhibition of JNK significantly increased both proliferation and viability of EL-4 cells treated with free doxorubicin, showing that the JNK signaling pathway could be critical for mediating cell death in EL-4 cells exposed to free doxorubicin. Both activation of caspase 3 and decreased binding activity of the p50 subunit of NFkappaB were observed in cells treated with free doxorubicin and HYD, while no such effects were seen in cells incubated with PK1. Analysis of the expression of genes involved in apoptosis and regulation of the cell cycle demonstrated that free doxorubicin and HYD have very similar mechanisms of action, while PK1 has very different characteristics.

000      
00000naa 2200000 a 4500
001      
bmc10000660
003      
CZ-PrNML
005      
20111210154737.0
008      
100113s2007 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kovář, Lubomír $7 xx0126758
245    14
$a The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line / $c Kovár L, Strohalm J, Chytil P, Mrkvan T, Kovár M, Hovorka O, Ulbrich K, Ríhová B.
314    __
$a Department of Immunology and Gnotobiology, Institute of Microbiology ASCR, v.v.i., VídenskA 1083, 142 20 Prague 4, Czech Republic. lkovar@biomed.cas.cz
520    9_
$a Doxorubicin is one of the most potent anti-tumor drugs with a broad spectrum of use. To reduce its toxic effect and improve its pharmacokinetics, we conjugated it to an HPMA copolymer carrier that enhances its passive accumulation within solid tumors via the EPR effect and decreases its cytotoxicity to normal, noncancer cells. In this study, we compared the antiproliferative, pro-survival, and death signals triggered in EL-4 cancer cells exposed to free doxorubicin and doxorubicin conjugated to a HPMA copolymer carrier via either enzymatically (PK1) or hydrolytically (HYD) degradable bonds. We have previously shown that the intracellular distribution of free doxorubicin, HYD, and PK1 is markedly different. Here, we demonstrated that these three agents greatly differ also in the antiproliferative effect and cell death signals they trigger. JNK phosphorylation sharply increased in cells treated with HYD, while treatment with free doxorubicin moderately decreased and treatment with PK1 even strongly decreased it. On the other hand, treatment with free doxorubicin greatly increased p38 phosphorylation, while PK1 and HYD increased it slightly. PK1 also significantly increased ERK phosphorylation, while both the free doxorubicin and HYD conjugate slightly decreased it. Long-term inhibition of JNK significantly increased both proliferation and viability of EL-4 cells treated with free doxorubicin, showing that the JNK signaling pathway could be critical for mediating cell death in EL-4 cells exposed to free doxorubicin. Both activation of caspase 3 and decreased binding activity of the p50 subunit of NFkappaB were observed in cells treated with free doxorubicin and HYD, while no such effects were seen in cells incubated with PK1. Analysis of the expression of genes involved in apoptosis and regulation of the cell cycle demonstrated that free doxorubicin and HYD have very similar mechanisms of action, while PK1 has very different characteristics.
650    _2
$a financování organizované $7 D005381
650    _2
$a akrylamidy $x analýza $x farmakologie $x chemie $7 D000178
650    _2
$a zvířata $7 D000818
650    _2
$a apoptóza $x genetika $7 D017209
650    _2
$a kaspasa 3 $x metabolismus $7 D053148
650    _2
$a CDC geny $7 D018816
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a viabilita buněk $7 D002470
650    _2
$a doxorubicin $x analýza $x farmakologie $x chemie $7 D004317
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a exprese genu $x účinky léků $7 D015870
650    _2
$a inhibiční koncentrace 50 $7 D020128
650    _2
$a lymfom T-buněčný $x chemie $x metabolismus $7 D016399
650    _2
$a myši $7 D051379
650    _2
$a mitogenem aktivované proteinkinasy kinas $x antagonisté a inhibitory $x metabolismus $7 D020929
650    _2
$a NF-kappa B $x metabolismus $7 D016328
650    _2
$a fosforylace $7 D010766
700    1_
$a Strohalm, Jiří $7 xx0109134
700    1_
$a Chytil, Petr. $7 _AN032430
700    1_
$a Mrkvan, Tomáš $7 xx0062385
700    1_
$a Kovář, Marek $7 xx0114168
700    1_
$a Hovorka, Ondřej, $d 1971- $7 xx0062705
700    1_
$a Ulbrich, Karel, $d 1947- $7 jo2004259877
700    1_
$a Říhová, Blanka, $d 1942- $7 jo20000073671
773    0_
$w MED00006454 $t Bioconjugate chemistry $g Roč. 18, č. 3 (2007), s. 894-902 $x 1043-1802
910    __
$a ABA008 $b x $y 8
990    __
$a 20090310084605 $b ABA008
991    __
$a 20100113144938 $b ABA008
999    __
$a ok $b bmc $g 703389 $s 565828
BAS    __
$a 3
BMC    __
$a 2007 $b 18 $c 3 $d 894-902 $i 1043-1802 $m Bioconjugate chemistry $x MED00006454
LZP    __
$a 2010-b1/ipme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...